{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:34:12Z","timestamp":1747172052543,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.urology.2018.05.035","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T02:23:32Z","timestamp":1529979812000},"page":"6-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hemorrhagic Cystitis Associated With Gefitinib Treatment: A Case Report"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-3687","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjing","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tieding","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2018.05.035_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.lungcan.2010.12.008","article-title":"Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence","volume":"71","author":"Gridelli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.urology.2018.05.035_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2018.05.035_bib0003","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer","volume":"26","author":"Maruyama","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2018.05.035_bib0004","first-page":"591","article-title":"Hemorrhagic cystitis: etiology and treatment","volume":"11","author":"Traxer","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2018.05.035_bib0005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0022-5347(17)43593-2","article-title":"Epidermal growth factor\u2014interactions with normal and malignant urothelium: in vivo and in situ studies","volume":"138","author":"Messing","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.05.035_bib0006","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/01.LAB.0000086380.23263.52","article-title":"Epidermal growth factor receptor regulates normal urothelial regeneration","volume":"83","author":"Daher","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.urology.2018.05.035_bib0007","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-05-2148","article-title":"Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation","volume":"12","author":"Nicolle","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2018.05.035_bib0009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.lungcan.2003.10.010","article-title":"Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer","volume":"43","author":"Argiris","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.urology.2018.05.035_bib0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10330-007-0135-z","article-title":"Unusual side effect and dramatic response from gefitinib as first-line use in a male-patient with bronchioloalveolar carcinoma","volume":"6","author":"Song","year":"2007","journal-title":"Chin-German J Clin Oncol"},{"key":"10.1016\/j.urology.2018.05.035_bib0011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2490-10-6","article-title":"Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report","volume":"10","author":"Arakawa","year":"2010","journal-title":"BMC Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518305557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518305557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T23:02:59Z","timestamp":1540594979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429518305557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":10,"alternative-id":["S0090429518305557"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2018.05.035","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemorrhagic Cystitis Associated With Gefitinib Treatment: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2018.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}